Twist Bioscience Reports Monday With Breakeven Timeline Now Three Quarters Away

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Twist Bioscience typically reports earnings before market open, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through momentum.

Historical price action around TWST earnings shows substantial volatility, with an average absolute Day 0 move of 10.23% and Day +1 follow-through averaging 3.55%. The stock has demonstrated a bearish bias in immediate reactions, with five of the past eight Day 0 moves negative, including three declines exceeding 10%.

The most extreme reaction came in August 2024, when shares plunged 19.00% on Day 0 before recovering 5.49% the following session—a pattern suggesting initial overreactions that partially reverse. More recently, the May 2026 report triggered a 6.97% Day 0 decline with minimal follow-through, while February 2026 saw a sharp 13.98% Day 0 rally that gave back ground on Day +1.

The wide Day 0 trading ranges—averaging 12.25%—reflect high uncertainty and active repositioning as investors digest results. Day +1 ranges remain elevated at 10.14%, indicating continued volatility extends beyond the initial reaction. Investors should prepare for significant price swings in both directions, with historical precedent suggesting moves of 10% or more are common regardless of whether results beat or miss estimates.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 17.75% for the August expiration, significantly higher than the stock's average historical Day 0 move of 10.23%. This elevated implied volatility suggests options traders are anticipating a larger-than-typical reaction to this earnings report, potentially reflecting heightened uncertainty around valuation sustainability after the stock's 154% rally or increased stakes around management's profitability guidance.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on Twist Bioscience with an average rating of 4.64 (Strong Buy territory) and a mean price target of $104.00, implying approximately 13.6% upside from the current price of $91.55. The consensus includes 9 Strong Buy ratings, 0 Moderate Buys, and 2 Hold ratings, with no sell recommendations.

However, sentiment has deteriorated over the past month, with the average recommendation slipping from 4.82 as one analyst downgraded from Strong Buy to Hold. This shift reflects growing caution about valuation after the stock's sharp appreciation, even as the broader analyst community remains constructive on the long-term opportunity.

Price targets span a wide range from $85 to $120, with the high-end estimate from Canaccord representing 31% upside and suggesting some analysts see significant additional appreciation potential if the company can demonstrate accelerating progress toward profitability. The mean target of $104 sits comfortably above current levels but below the most optimistic forecasts, indicating the Street sees modest near-term upside with execution risk balanced against the company's positioning in high-growth synthetic biology markets.

Part 4: Technical Picture

Twist Bioscience enters earnings with strong technical momentum, as the Barchart Technical Opinion registers a 96% Buy signal, up from 88% one week ago and down slightly from 100% one month ago. This elevated reading reflects robust near-term momentum despite the stock trading near recent highs.

Timeframe Analysis:

• Short-term (100% Buy): Maximum bullish signal indicates powerful near-term momentum heading into the earnings event
• Medium-term (100% Buy): Sustained strength across the intermediate timeframe confirms the uptrend remains intact
• Long-term (100% Buy): Maximum long-term buy signal reflects the stock's transformation from a $52 level six months ago to current levels

Strong Strongest trend characteristics indicate TWST is exhibiting maximum momentum across all timeframes, creating an environment where the stock enters earnings with significant technical support but also elevated expectations that results must meet to sustain the rally.

The stock is trading at $91.55, positioned above all major moving averages including the 5-day ($88.69), 20-day ($91.44), 50-day ($83.51), 100-day ($67.90), and 200-day ($52.58). This alignment with the current price sitting just above the 20-day average suggests the stock is testing resistance at recent highs while maintaining support from rising intermediate and long-term trend lines. The technical setup is supportive heading into earnings, but the proximity to the 20-day moving average and the stock's extended position above longer-term averages creates a scenario where a disappointment could trigger profit-taking, while a beat might struggle to generate significant upside given the already-stretched valuation and recent rally. Key support on any pullback would likely emerge at the 50-day moving average around $83.50, while a breakout above $92 would target the $104 analyst consensus price target.